Rx License-Rx

22-9930-tpNCS

Compositions and Methods for Enhancing the Anti-Tumor Activity of CAR T Cells by Co-Expression of CH25H

Co-expression of modified chimeric antigen receptor (CAR) T cells and cholesterol 25-hydroxylase (CH25H) in a single construct for treatment of solid tumor and hematological cancers. Problem: CAR T cell therapy is a treatment in which T cells collected from a patient are engineered to produce CARs that recognize and attack cancer cells. While it is efficacious at treating some patients with hematologic malignancies, many patients relapse and there is little success at treating solid tumors, which represent ~90% of adult cancers and 40% of childhood cancers. Cancer cells can evade CAR T therapy through trogocytosis, whereby an antigen on cancer cells is transferred to cytotoxic T lymphocytes (CTLs). This causes CTLs to become exhausted, be mistakenly recognized as targets and killed, and allows cancer cells to survive. Partial loss of CH25H in intratumoral T cells leads to increased trogocytosis and suppresses the viability and...

Intelligence Memo

Owner: University of Pennsylvania

Core category: Therapeutics

Therapeutic area: Oncology

Indication: Cancer

Modality: Cell/Gene Therapy

Focus tags: Oncology, Immunology, Cardiometabolic

Technology tags: Cell/Gene Therapy

Mechanism:

Development stage: Preclinical

Patent status: US Paten Pending

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Oncology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with University of Pennsylvania. The practical first use case is Cancer. Public description: Co-expression of modified chimeric antigen receptor (CAR) T cells and cholesterol 25-hydroxylase (CH25H) in a single construct for treatment of solid tumor and hematological cancers. Problem: CAR T cell therapy is a treatment in which T.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Oncology remains highly partnerable: Pharma buyers still pay attention when an asset can be tied to biomarkers, combinations, resistance biology, or a defined tumor segment.

Hot modality with strategic appetite: Cell and gene therapy buyers care when there is a crisp antigen, genetic subgroup, potency assay, or manufacturing shortcut.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Manufacturing can dominate the budget: Potency assays, vector or cell process reproducibility, release testing, and COGS can become bigger risks than the biology.

Competitive field may be crowded: Oncology buyers will ask why this is better than existing modalities, combinations, and biomarker strategies already in the clinic.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets BMS / 2seventy — Cell therapy portfolio logic; needs differentiated antigen strategy. Gilead / Kite — Manufacturing and oncology BD infrastructure already exists. Regeneron — Deep oncology biologics and T-cell engager adjacency.

Development Strategy to Increase PoS

First indication: Cancer

Study design: Biomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.

Key experiments Validate the AI-optimized pivot: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero

Best next experiment: Run the smallest independent study that validates: Use a centralized CDMO, lock the release assay early, and design the first trial around tumor-antigen evidence rather than broad basket ambition.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.